Source: Eur Respir J 2016; 47: 564-574
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Pym Alexander S., Diacon Andreas H., Tang Shen-Jie, Conradie Francesca, Danilovits Manfred, Chuchottaworn Charoen, Vasilyeva Irina, Andries Koen, Bakare Nyasha, De Marez Tine, Haxaire-Theeuwes Myriam, Lounis Nacer, Meyvisch Paul, Van Baelen Ben, van Heeswijk Rolf P.G., Dannemann Brian. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis. Eur Respir J 2016; 47: 564-574

Member's Comments

No comment yet.

Related content which might interest you: Linezolid in the treatment of multi- and extensively drug-resistance tuberculosis Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011 Treatment of TB Source: Eur Respir Mon 2012; 58: 154-166 Year: 2012 Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases Source: Eur Respir J 2008; 31: 1155-1159 Year: 2008 First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline Source: Eur Respir J 2016; 48: 935-938 Year: 2016 Should we worry about bedaquiline exposure in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis? Source: Eur Respir J, 55 (2) 1901908; 10.1183/13993003.01908-2019 Year: 2020 Treatment options for patients with multidrug-resistant or extensively drug-resistant tuberculosis Source: Annual Congress 2009 - Priorities in tuberculosis research Year: 2009 Early access to bedaquiline for extensively drug-resistant (XDR) and pre-XDR tuberculosis Source: Eur Respir J, 54 (1) 1802208; 10.1183/13993003.02208-2018 Year: 2019 Multidrug- and extensively drug-resistant tuberculosis: an emerging threat Source: Eur Respir Rev 2009; 18: 195-197 Year: 2009 Treatment of drug-susceptible and drug-resistant tuberculosis Source: Eur Respir Monogr 2018; 82: 152-178 Year: 2018 Linezolid in multidrug-resistant tuberculosis treatment Source: Eur Respir J 2004; 24: Suppl. 48, 485s Year: 2004 Trend in rifampicin-, multidrug- and extensively drug-resistant tuberculosis in Italy, 2009–2016 Source: Eur Respir J, 52 (1) 1800070; 10.1183/13993003.00070-2018 Year: 2018 Linezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India Source: Eur Respir J 2012; 39: 956-962 Year: 2012 Is bedaquiline as effective as fluoroquinolones in the treatment of multidrug-resistant tuberculosis? Source: Eur Respir J 2016; 48: 582-585 Year: 2016 Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB Source: Eur Respir J 2009; 33: 1085-1094 Year: 2009 Treating extensively drug resistant tuberculosis (XDR-TB) in India Source: Annual Congress 2008 - Epidemiology and clinical management of multidrug-resistant and extensively drug-resistant tuberculosis Year: 2008 Clinical and operational value of the extensively drug-resistant tuberculosis definition Source: Eur Respir J 2007; 30: 623-626 Year: 2007 Bedaquiline-based treatment regimen for multidrug-resistant tuberculosis Source: Eur Respir J, 49 (5) 1700742; 10.1183/13993003.00742-2017 Year: 2017 Mefloquine as a potential drug against multidrug-resistant tuberculosis Source: Eur Respir J 2015; 46: 1503-1505 Year: 2015 A case of resistance beyond extensively drug-resistant tuberculosis in Japan Source: Eur Respir J 2013; 42: 872-873 Year: 2013 A case of resistance beyond extensively drug-resistant tuberculosis in Japan Source: Eur Respir J 2013; 42: 870-872 Year: 2013